Belite Bio, Inc Stock-Based Compensation
Belite Bio, Inc (BLTE) reported Stock-Based Compensation of $38.92 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-03-31
| Period end | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|
| 2025-12-31 | $38.92M 20-F · filed 2026-03-31 |
| 2024-12-31 | $8.99M 20-F · filed 2026-03-31 |
| 2023-12-31 | $3.82M 20-F · filed 2026-03-31 |
| 2022-12-31 | $1.48M 20-F · filed 2025-03-17 |
| 2021-12-31 | $1.53M 20-F · filed 2024-03-12 |
| 2020-12-31 | $1.36M 20-F · filed 2023-03-31 |